Lysophosphatidic acid inhibits apoptosis induced by cisplatin in cervical cancer cells

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Sui, Yanxia ^a,b   Yang, Ya ^a   Wang, Ji ^c   Li, Yi ^b   Ma, Hongbing ^d   Cai, Hui ^a   Liu, Xiaoping ^a   Zhang, Yong ^c   Wang, Shufeng ^b   Li, Zongfang ^d   Zhang, Xiaozhi ^a   Wang, Jiansheng ^b   Liu, Rui ^a   Yan, Yanli ^a   Xue, Chaofan ^a   Shi, Xiaowei ^a   Tan, Li ^a   Ren, Juan ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^c Medical School Xi'An Jiaotong University ^*  (China)

^d THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; FAS LIGAND; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; FAS ANTIGEN; FASLG PROTEIN, HUMAN; LYSOPHOSPHOLIPID; PROTEIN BAD;

APOPTOSIS; ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING; DRUG EFFECTS; ENZYME ACTIVATION; HELA CELL LINE; METABOLISM; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS;

ANTIGENS, CD95; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CASPASE 3; CELL LINE, TUMOR; CISPLATIN; ENZYME ACTIVATION; FAS LIGAND PROTEIN; FEMALE; HELA CELLS; HUMANS; LYSOPHOSPHOLIPIDS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS;

EID: 84940882918     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/598386     Document Type: Article

References (40)

1. J. R. Erickson, Y. Hasegawa, X. Fang et al., "Lysophosphatidic acid and ovarian cancer: a paradigm for tumorogenesis and patient management," Prostaglandins and Other Lipid Mediators, vol. 64, no. 1-4, pp. 63-81, 2001.
2. Y. Xu, Z. Z. Shen, D. W. Wiper et al., "Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers," The Journal of the AmericanMedical Association, vol. 280, no. 8, pp. 719-723, 1998.
3. J. S. Karliner, "Lysophospholipids and the cardiovascular system," Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, vol. 1582, no. 1-3, pp. 216-221, 2002.
4. C. Schulze, C. Smales, L. L. Rubin, and J. M. Staddon, "Lysophosphatidic acid increases tight junction permeability in cultured brain endothelial cells," Journal of Neurochemistry, vol. 68, no. 3, pp. 991-1000, 1997.
5. I. Ishii, N. Fukushima, X. Ye, and J. Chun, "Lysophospholipid receptors: signaling and biology," Annual Review of Biochemistry, vol. 73, pp. 321-354, 2004.
6. T. S. Panetti, "Differential effects of sphingosine 1-phosphate and lysophosphatidic acid on endothelial cells," Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, vol. 1582, no. 1-3, pp. 190-196, 2002.
7. Z. Z. Shen, M. Z. Wu, P. Elson et al., "Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases," Gynecologic Oncology, vol. 83, no. 1, pp. 25-30, 2001.
8. M. M. Murph, "Agonist-induced endocytosis of lysophosphatidic acid-coupled LPA1/EDG-2 receptors via a dynamin2-and Rab5-dependent pathway," Journal of Cell Science, vol. 116, no. 10, pp. 1969-1980, 2003.
9. L. M. Baudhuin, K. L. Cristina, J. Lu, and Y. Xu, "Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen-activated protein kinase and is cell-line specific," Molecular Pharmacology, vol. 62, no. 3, pp. 660-671, 2002.
10. R.-J. Chen, S.-U. Chen, C.-H. Chou, and M.-C. Lin, "Lysophosphatidic acid receptor 2/3-mediated IL-8-dependent angiogenesis in cervical cancer cells," International Journal of Cancer, vol. 131, no. 4, pp. 789-802, 2012.
11. J. W. Choi, S. Lim, Y.-S. Oh et al., "Subtype-specific role of phospholipase C-β in bradykinin and LPA signaling through differential binding of different PDZ scaffold proteins," Cellular Signalling, vol. 22, no. 7, pp. 1153-1161, 2010.
12. Y. Kishi, S. Okudaira, M. Tanaka et al., "Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine TO lysophosphatidic acid," The Journal of Biological Chemistry, vol. 281, no. 25, pp. 17492-17500, 2006.
13. A. Eastman, "The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes," Pharmacology andTherapeutics, vol. 34, no. 2, pp. 155-166, 1987.
14. K. Wozniak and J. Blasiak, "Recognition and repair of DNAcisplatin adducts," Acta Biochimica Polonica, vol. 49, no. 3, pp. 583-596, 2002.
15. A. Basu and S. Krishnamurthy, "Cellular responses to cisplatininduced DNA damage," Journal of Nucleic Acids, vol. 2010, Article ID 201367, 16 pages, 2010.
16. A. Efeyan and M. Serrano, "p53: guardian of the genome and policeman of the oncogenes," Cell Cycle, vol. 6, no. 9, pp. 1006-1010, 2007.
17. O. Kutuk, E. D. Arisan, T. Tezil, M. C. Shoshan, and H. Basaga, "Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation," Carcinogenesis, vol. 30, no. 9, pp. 1517-1527, 2009.
18. C. M. Yan, E. Q. Chai, H. Y. Cai, G. Miao, and W. Ma, "Oleuropein induces apoptosis via activation of caspases and suppression of phosphatidylinositol 3-kinase/protein kinase B pathway in HepG2 human hepatoma cell line," Molecular Medicine Reports, vol. 11, pp. 4617-4624, 2015.
19. X. Y. Wang, X. S. Fan, L. Cai, S. Liu, X. F. Cong, and X. Chen, "Lysophosphatidic acid rescues bone mesenchymal stem cells from hydrogen peroxide-induced apoptosis," Apoptosis, vol. 20, no. 3, pp. 273-284, 2015.
20. A. Brozovic, G. Fritz, M. Christmann et al., "Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance," International Journal of Cancer, vol. 112, no. 6, pp. 974-985, 2004.
21. Y. Q. Liu, H. Xing, X. B. Han et al., "Apoptosis of HeLa cells induced by cisplatin and its mechanism," Journal of Huazhong University of Science and Technology-Medical Science, vol. 28, no. 2, pp. 197-199, 2008.
22. K. L. Jin, J.-Y. Park, E. J. Noh et al., "The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells," Journal of Gynecologic Oncology, vol. 21, no. 4, pp. 262-268, 2010.
23. T. Sakaeda, T. Nakamura, M. Hirai et al., "MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling," Pharmaceutical Research, vol. 19, no. 9, pp. 1323-1329, 2002.
24. K. Kandasamy, S. M. Srinivasula, E. S. Alnemri et al., "Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release," Cancer Research, vol. 63, no. 7, pp. 1712-1721, 2003.
25. H. Toyota, N. Yanase, T. Yoshimoto, M. Moriyama, T. Sudo, and J. Mizuguchi, "Calpain-induced Bax-cleavage product is a more potent inducer of apoptotic cell death thanwild-type Bax," Cancer Letters, vol. 189, no. 2, pp. 221-230, 2003.
26. Y. R. Meng, S. J. Kang, and D. A. Fishman, "Lysophosphatidic acid inhibits anti-Fas-mediated apoptosis enhanced by actin depolymerization in epithelial ovarian cancer," FEBS Letters, vol. 579, no. 5, pp. 1311-1319, 2005.
27. Y. Meng, S. Kang, J. So, S. Reierstad, and D. A. Fishman, "Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis," Gynecologic Oncology, vol. 96, no. 2, pp. 462-469, 2005.
28. X. Wan, Y. Yokoyama, A. Shinohara, Y. Takahashi, and T. Tamaya, "PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway," Cell Death and Differentiation, vol. 9, no. 4, pp. 414-420, 2002.
29. J. Yu, Y. Zhang, J. Mcilroy, T. Rordorf-Nikolic, G. A. Orr, and J. M. Backer, "Regulation of the p85/p110 phosphatidylinositol 3′ -kinase: stabilization and inhibition of the p110α catalytic subunit by the p85 regulatory subunit," Molecular and Cellular Biology, vol. 18, no. 3, pp. 1379-1387, 1998.
30. M. S. Kim, J. H. Kim, Y. Bak et al., "2, 4-bis (p-hydroxyphenyl)-2-butenal (HPB242) induces apoptosis via modulating E7 expression and inhibition of PI3K/Akt pathway in SiHa human cervical cancer cells," Nutrition and Cancer, vol. 64, no. 8, pp. 1236-1244, 2012.
31. F. Cui, X. L. Li, X. Y. Zhu et al., "MiR-125b inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting phosphoinositide 3-kinase catalytic subunit delta," Cellular Physiology and Biochemistry, vol. 30, no. 5, pp. 1310-1318, 2012.
32. S. Kang, S. M. Dong, B.-R. Kim et al., "Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells," Apoptosis, vol. 17, no. 9, pp. 989-997, 2012.
33. O. Thanaketpaisarn, P. Waiwut, H. Sakurai, and I. Saiki, "Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-κB and PI3K/Akt signaling pathways," International Journal of Oncology, vol. 39, no. 1, pp. 279-285, 2011.
34. X. Wang, J.-H. Ren, F. Lin et al., "Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway," Cancer Biology and Therapy, vol. 10, no. 6, pp. 632-643, 2010.
35. C. W. Lee, N. H. Kim, H. K. Choi et al., "Lysophosphatidic acid-induced c-fos up-regulation involves cyclic AMP response element-binding protein activated by mitogen-and stressactivated protein kinase-1," Journal of Cellular Biochemistry, vol. 104, no. 3, pp. 785-794, 2008.
36. D. W. Hommes, M. P. Peppelenbosch, and S. J. H. van Deventer, "Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets," Gut, vol. 52, no. 1, pp. 144-151, 2003.
37. M. Mukai, F. Imamura, M. Ayaki et al., "Inhibition of tumor invasion andmetastasis by a novel lysophosphatidic acid (cyclic LPA)," International Journal ofCancer, vol. 81, no. 6, pp. 918-922, 1999.
38. E.-Y. Huang, Y.-F. Chen, Y.-M. Chen et al., "A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells," Cell Death and Disease, vol. 3, no. 1, article e251, 2012.
39. W.-H. Su, P.-C. Chuang, E.-Y. Huang, and K. D. Yang, "Radiation-induced increase in cell migration and metastatic potential of cervical cancer cells operates via theK-ras pathway," The American Journal of Pathology, vol. 180, no. 2, pp. 862-871, 2012.
40. H. Rincon-Arano, R. Rosales, N. Mora, A. Rodriguez-Castaneda, and C. Rosales, "R-Ras promotes tumor growth of cervical epithelial cells," Cancer, vol. 97, no. 3, pp. 575-585, 2003.